A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation.

Thomas Ihle Aarhus, Jan Eickhoff, Bert Klebl, Anke Unger, Joanna Boros, Axel Choidas, Mia-Lisa Zischinsky, Camilla Wolowczyk, Geir Bjørkøy, Eirik Sundby, Bård Helge Hoff

European journal of medicinal chemistry 2023 Jul 05

filter terms:

The colony-stimulating factor 1 receptor (CSF1R) plays an important role in the regulation of many inflammatory processes, and overexpression of the kinase is implicated in several disease states. Identifying selective, small-molecule inhibitors of CSF1R may be a crucial step toward treating these disorders. Through modelling, synthesis, and a systematic structure-activity relationship study, we have identified a number of potent and highly selective purine-based inhibitors of CSF1R. The optimized 6,8-disubstituted antagonist, compound 9, has enzymatic IC50 of 0.2 nM, and displays a strong affinity toward the autoinhibited form of CSF1R, contrasting that of other previously reported inhibitors. As a result of its binding mode, the inhibitor shows excellent selectivity (Selectivity score: 0.06), evidenced by profiling towards a panel of 468 kinases. In cell-based assays, this inhibitor shows dose-dependent blockade of CSF1-mediated downstream signalling in murine bone marrow-derived macrophages (IC50 = 106 nM) as well as disruption of osteoclast differentiation at nanomolar levels. In vivo experiments, however, indicate that improve metabolic stability is needed in order to further progress this compound class. Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Citation

Thomas Ihle Aarhus, Jan Eickhoff, Bert Klebl, Anke Unger, Joanna Boros, Axel Choidas, Mia-Lisa Zischinsky, Camilla Wolowczyk, Geir Bjørkøy, Eirik Sundby, Bård Helge Hoff. A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation. European journal of medicinal chemistry. 2023 Jul 05;255:115344